US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung ...
Bayer announced that the investigational compound sevabertinib (BAY 2927088) has been granted Priority Review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose …